Post-earnings recap
Reported
Mon, Aug 4, 2025
EPS actual
$0.17
EPS est.
$0.27
EPS surprise
-35.85%
1-day move
-17.99%
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a disappointing EPS, falling short of expectations, which contributed to a significant drop in stock price. The lack of revenue details and guidance adds uncertainty for investors. The management's defensive tone suggests they are cautious about the company's near-term prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.17 | N/A | -35.85% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current market conditions impacting performance. They highlighted the importance of strategic adjustments moving forward.
Management acknowledged the challenges faced during the quarter.
They emphasized the need for continued focus on operational efficiency.